INFLIXIMAB

infliximab 100 mg injection, 1 vial

INFLIXIMAB (6397Q)

infliximab 100 mg injection, 1 vial
6397Q
Body System:
Manner of administration:Injection
Private
S100 HSD Private
Authority Required

Restriction

Indication: Severe active rheumatoid arthritis
Treatment phase: Initial treatment - Initial 1 (new patient)

Restriction

Indication: Severe active rheumatoid arthritis
Treatment phase: Initial treatment - Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months)

Restriction

Indication: Severe active rheumatoid arthritis
Treatment phase: Initial treatment - Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months)

Restriction

Indication: Severe active rheumatoid arthritis
Treatment phase: Initial 1 (new patient) or Initial 2 (change or recommencement of treatment after a break in biological medicine of less than 24 months) or Initial 3 (recommencement of treatment after a break in biological medicine of more than 24 months) - balance of supply

Restriction

Indication: Severe active rheumatoid arthritis
Treatment phase: First continuing treatment

Restriction

Indication: Severe active rheumatoid arthritis
Treatment phase: First continuing treatment - balance of supply
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 1 # of repeats: 0 DPMQ: $202.49 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
Inflectra
Ixifi
Remicade
Remsima
Renflexis